OPKO Flips Nausea Drug Rolapitant to Tesaro for $121M
By Catherine Shaffer
Wednesday, December 15, 2010
Tesaro Inc. has acquired rights to nausea drug rolapitant and one other drug from OPKO Health Inc. for $121 million Including milestones, double-digit, tiered royalties and a 10 percent equity position in Tesaro. Rolapitant was a Schering-Plough Corp. property, but OPKO nabbed it for just $2 million up front following Schering's 2009 merger with Merck and Co. Inc.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.